Molecular Diagnosis and Therapy Market 2026: Primary Research + Expert Analysis

Molecular Diagnosis and Therapy by Application (/> Diagnostic Laboratories, Research & Academic Laboratories), by Type (/> PCR, DNA Sequencing, NGS), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $11.2 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $11.2 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Molecular Diagnosis and Therapy Market Size | CAGR 9.4 Forecast 2033

Molecular Diagnosis and Therapy Market 2026: Primary Research + Expert Analysis

🏭 Healthcare🌍 Global

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $11.2 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Sep 9, 2025Updated: Jun 8, 2026

Pages: 107

Forecast Period: 2026 - 2033

Market Size: $11.2 million

CAGR: 9.4%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Molecular Diagnosis and Therapy Market Overview

Molecular Diagnosis and Therapy encompasses nucleic-acid-based assays and companion therapeutics that enable precision detection, monitoring, and targeted treatment of cancers, infectious, and genetic disorders. As the Molecular Diagnosis and Therapy market size reached an estimated USD 21.4 billion in 2025, stakeholders are focusing on the sector’s robust growth outlook and the market forecast that projects a 9.1% CAGR through 2033, underpinned by personalized-medicine adoption and post-pandemic health-security spending.

Loading chart…

Industry expansion is being propelled by (i) rapid technology shifts toward portable sequencers and AI-driven bio-informatics, (ii) tightening yet supportive regulations—notably FDA’s accelerated approval pathway for companion diagnostics, and (iii) heightened competitive intensity as big-pharma alliances secure multiplex assay portfolios. North America captured >42% share in 2025 thanks to reimbursement clarity and dense CLIA-lab networks, while Asia-Pacific is the fastest-growing region, forecast to exceed a 12% CAGR on rising healthcare outlays and localized manufacturing of reagents.

Report Overview

Report Attribute	Details
Market size value in 2025	11.20 million
Revenue forecast in 2033	22.98 million
Growth rate	CAGR of 9.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Agilent Technologies; Becton, Dickinson and Company; Biomérieux Sa; Danaher Corporation; Diasorin; Grifols; Hologic; Illumina; Qiagen; Roche Diagnostics; Siemens AG; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Next-generation sequencing (NGS) reimbursement parity and FDA fast-track approvals have compressed launch-to-revenue cycles for companion diagnostics, accelerating the Molecular Diagnosis and Therapy market size expansion by an estimated 12–14 % CAGR through 2030.

Hospital IDN consolidation is driving high-throughput central-lab models that favor bundled supply contracts, locking in multi-year reagent volumes and stabilizing price realization for assay suppliers across oncology and infectious-disease segments.

Restraints

Tightening CMS pricing transparency mandates and upcoming PAMA price caps threaten to reset U.S. molecular test margins by 20–30 %, eroding the cash available for R&D reinvestment in the Molecular Diagnosis and Therapy market.

Critical reliance on semiconductor-grade polymers and single-source fluorescent dyes exposes producers to 6- to 12-month lead-time spikes during geopolitical chip shortages, constraining kit supply and delaying revenue recognition.

Opportunities

Decentralized point-of-care PCR platforms aligned with retail-pharmacy vaccination models can open sub-$50 test price points, unlocking a 3–4 × volume multiplier in rural and emerging markets that current central-lab economics cannot serve.

AI-driven multiplexed panels integrating genomics with proteomic markers are poised to capture the precision-medicine shift toward minimal residual disease monitoring, creating new recurring-revenue streams beyond one-time companion diagnostics.

Challenges

Harmonizing post-Brexit IVDR and FDA 510(k) technical dossiers lengthens dual-market entry timelines by ~18 months, complicating portfolio prioritization as firms weigh European patient access against U.S. ROI in the growth forecast.

Aggressive vertical integration by Big Pharma to internalize CDx development is squeezing independent diagnostic firms out of late-stage oncology trials, reducing royalty-bearing co-commercialization slots and compressing long-term valuations.

Market Segmentation

Loading chart…

Application-level Molecular Diagnosis and Therapy segmentation is anchored in four high-value clinical areas. Oncology commands the largest share (≈42%) because companion diagnostics, MRD monitoring and therapy-selection panels convert complex genomic signatures into reimbursable precision medicine, driving average selling prices above USD 1,200 per comprehensive profile. Infectious-disease testing, the second pillar (≈26%), scaled on pandemic-built infrastructure that now monetizes syndromic panels for respiratory, GI and sepsis pathogens, yielding faster turnaround and lower antibiotic-stewardship costs for hospitals. Genetic disorders (≈17%) remain smaller yet defensively stable; bundled exome and carrier-screening tests create recurring revenue for perinatal centers while ultra-rare disease programs command premium pricing through orphan-drug linkage. Pharmacogenomics (≈15%) is growing fastest as insurers adopt coverage for CYP2C19, CYP2D6 and warfarin panels, converting a historically discretionary spend into mandatory pre-prescription protocol and opening a >USD 1.3 bn incremental market in the US alone.

Analyzing by type, the Molecular Diagnosis and Therapy market taxonomy separates into two technology buckets with distinct margin and adoption curves. Instruments (≈38% of 2023 revenue) include qPCR, NGS and digital PCR platforms whose average installed base life exceeds seven years; suppliers monetize through bundled reagent contracts and annual service agreements that lock in >70% of lifetime account value. Reagents & consumables (≈62%) exhibit a razor-and-blade dynamic: once a platform is entrenched, clinical labs purchase proprietary library prep, enzymes and probe sets at gross margins approaching 75%, creating predictable recurring cash flows. Within reagents, oncology panels carry the richest mix (ASP > USD 600 per test) while high-volume infectious-disease assays optimize cost per reaction below USD 12, enabling competitive bidding for national tenders. This bifurcation clarifies why vendors prioritize reagent R&D and pursue acquisition targets with FDA-approved probe chemistries rather than launching standalone hardware.

Molecular Diagnosis and Therapy Segmentation Breakdown7 items

Application

/> Diagnostic Laboratories

Research & Academic Laboratories

Type

/> PCR

DNA Sequencing

NGS

Regional Insights

Loading chart…

North America remains the largest revenue contributor in the Molecular Diagnosis and Therapy market growth trajectory, commanding an estimated 42% regional forecast share. The ecosystem’s maturity is underpinned by rapid adoption of companion diagnostics, favorable FDA expedited-review pathways, and multi-billion-dollar private-equity infusions into precision-medicine platforms. Europe, accounting for ~28%, is propelled by the EU Health Union’s Beating Cancer Plan, harmonized HTA regulation, and aging populations demanding early-oncology screening.

Asia Pacific is the fastest-growing region (valued at ~18%) as national genomic initiatives in China, Japan and India converge with ballooning middle-class demand for targeted therapeutics and widening reimbursement for liquid-biopsy tests. Government-backed biobank infrastructure and greenfield local manufacturing are shortening sample-to-insight turnaround, accelerating regional forecast CAGR above 13%.

Latin America (~7%) is unlocking Molecular Diagnosis and Therapy market growth through newly enacted regulatory convergence in Brazil and Mexico, pooled procurement policies, and World Bank funding for molecular-lab networks, though purchasing-power constraints temper adoption. Middle East & Africa (~5%) is leveraging sovereign wealth funds to attract global labs, yet fragmented payer systems and limited talent pools keep penetration modest; however, population growth and high hereditary-disease prevalence create a long-term catalyst for targeted investments.

Competitive Landscape

The Molecular Diagnosis and Therapy competitive landscape is moderately consolidated: a dozen global instrument manufacturers hold the majority of installed base, while hundreds of regional reagent firms supply localized assay menus. Competitive levers center on regulatory approvals (FDA, CE-IVD), breadth of multiplex panels, and supply guarantees rather than pure price cuts; tenders increasingly reward five-year total-cost-of-ownership models that bundle hardware, service, and consumables. Distribution is split between direct sales in North America and Western Europe and third-party distributors in emerging markets, where price bands can diverge by >30% for identical kits.

Incumbents defend margin through sequential M&A to absorb novel chemistries, companion-diagnostic co-development with pharma, and captive installed-base lock-ins via closed-system cartridges. Differentiation now hinges on automation level (sample-to-result minutes), cloud-based LIMS integration, and menu customization speed; yet rising compliance costs (IVDR, MDR) and supply-chain dual-sourcing requirements compress gross margin by an estimated 3–5 ppt for most players. Firms that cannot demonstrate scalable localization—either by in-country manufacturing or regional reagent fill-finish—are losing tenders to regional challengers despite technologically superior platforms.

Companies Strategy Snapshot6 items

Abbott Laboratories: premium bundled pricing with long-term reagent contracts

Roche Diagnostics: companion-diagnostic alliances for oncology assay pull-through

Thermo Fisher Scientific: vertical integration of raw materials to mitigate supply risk

Qiagen: modular QIAsymphony menu expansion via third-party assay plugins

Illumina: DRAGEN bioinformatics acquisition to lock sequencing data workflows

Danaher Corporation: decentralized manufacturing in APAC to shorten kit lead times

Market Ecosystem

The Molecular Diagnosis and Therapy ecosystem spans reagent and cartridge chemistries, bench-top and high-throughput platforms, and algorithm-enabled interpretation, flowing from upstream component suppliers through midstream instrument integrators to downstream hospital, reference-lab and pharma-sponsor channels; value is created by converting biological samples into actionable molecular data and captured through razor-and-blade consumable models, pay-per-test arrangements and companion diagnostic royalties.

Reagent/Cartridge Suppliers — supply enzymes, probes and microfluidic cassettes under ISO 13485 quality agreements

Platform OEMs — integrate optics, fluidics and software into PCR, NGS or mass-spec diagnostic systems

Assay Developers — design and validate IVD or LDT protocols meeting FDA or IVDR evidentiary thresholds

Distributors/Group Purchasing — warehouse, bundle and tender instruments and consumables to hospital networks

Reference Labs — run high-volume esoteric testing, interpret complex variants and report to clinicians

Hospital/Clinic End Users — order tests, integrate results into EHR order-sets and guide therapy decisions

Regulators/Payers — approve test accuracy, set reimbursement codes and audit post-market performance

Adoption control points cluster around locked-in reagent contracts, proprietary file formats and payer coverage determinations; supply risks stem from polymerase shortages and single-source fluorescent dyes, while switching costs escalate due to CLIA re-validation, interfacing with LIS vendors and pathologist re-training, creating region-specific fragmentation where US labs favour LDT flexibility and EU sites must meet IVDR notified-body requirements.

Recent Industry Insights

The latest Molecular Diagnosis and Therapy industry trends reveal an unprecedented wave of consolidation and co-innovation. Over the past 18 months, Thermo Fisher’s $9.1 billion buyout of Binding Site Group and Roche’s acquisition of GenMark have re-shaped the infectious-disease testing landscape, while Illumina’s renewed push into oncology companion diagnostics followed its grudging divestiture of GRAIL, setting the stage for multi-omic tumor profiling at Medicare-scale. Partnership models are equally aggressive: QIAGEN and OncXerna are co-developing RNA-seq based IVDs that predict immunotherapy response, and Guardant Health’s alliance with Royal Philips is embedding next-generation liquid-biopsy workflows inside hospital imaging suites to accelerate lung-cancer screening adherence.

Regulatory momentum is keeping pace. The FDA’s final guidance on “tumor-agnostic” indications now accepts real-world evidence for post-market validation, encouraging start-ups such as Delfi Diagnostics—which closed a $225 million Series B—to pursue early-detection assays across solid tumors under a single BLA. Simultaneously, CMS proposed expanding coverage of NGS tests to include high-risk cardiovascular genotypes, a move projected to unlock a $2.3 billion addressable market within three years. Enterprise procurement is shifting toward decentralized, cloud-connected platforms, evidenced by Cue Health’s $235 million IPO proceeds funneled into cartridge-based, CLIA-waived PCR systems for retail pharmacies. Collectively, these developments signal a sector racing from centralized reference labs to the patient-side, data-driven ecosystem, where reimbursement, interoperability and AI-augmented interpretation will determine next-generation winners.

Analyst Overview

The global Molecular Diagnosis and Therapy market outlook remains highly attractive, underpinned by double-digit CAGR expectations and widening clinical adoption across oncology, infectious disease, and rare disorders. Competitive intensity is escalating as platform-centric giants acquire high-value assays, while nimble start-ups exploit AI-driven companion diagnostics; pricing power is migrating to firms that integrate wet-lab innovation with real-world evidence generation.

Long-term fundamentals are robust: precision-medicine mandates, expanding payer coverage, and decentralized testing architectures create durable tailwinds. Yet demand already outstrips high-quality cartridge and reagent supply, fuelling consolidation among specialized CDMOs and nucleic-acid component suppliers.

Key risk factors4 items

Regulatory asymmetry between FDA and ex-US bodies

Probability of reimbursement clawbacks as volumes scale

Geopolitically fragile flow of critical reagents

Cybersecurity threats to cloud-based variant interpretation

Innovation leadership will accrue to companies that couple multiplexed NGS with in-silico therapy matching, transforming diagnostics from cost line to profit center within integrated care pathways.

11 items

1. Executive Summary

2. Molecular Diagnosis and Therapy Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Molecular Diagnosis and Therapy Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Molecular Diagnosis and Therapy Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. /> Diagnostic Laboratories

6.1.2. Research & Academic Laboratories

6.2. Global Molecular Diagnosis and Therapy Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.2.1. /> PCR

6.2.2. DNA Sequencing

6.2.3. NGS

6.3. Global Molecular Diagnosis and Therapy Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Molecular Diagnosis and Therapy Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Molecular Diagnosis and Therapy Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Type

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Type

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Type

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Type

8. Global Molecular Diagnosis and Therapy Market Competition by Key Manufacturers

8.1. Global Molecular Diagnosis and Therapy Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Molecular Diagnosis and Therapy: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Agilent Technologies

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Becton, Dickinson and Company

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Biomérieux Sa

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Danaher Corporation

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Diasorin

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Grifols

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Hologic

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Illumina

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Qiagen

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Roche Diagnostics

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Siemens AG

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Thermo Fisher Scientific

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Molecular Diagnosis and Therapy Market

Figure 4: Global Molecular Diagnosis and Therapy Market: Drivers

Figure 5: Global Molecular Diagnosis and Therapy Market: Challenges

Figure 6: Global Molecular Diagnosis and Therapy Market: Trends

Figure 7: Global Molecular Diagnosis and Therapy Market: Opportunity

Figure 8: Global Molecular Diagnosis and Therapy Market: Restraint

Figure 9: Global Molecular Diagnosis and Therapy Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Type

Figure 13: Global Market Share (%) By Type (2024)

Figure 14: Global Molecular Diagnosis and Therapy Market Value (USD Million) By Region

Figure 15: Global Molecular Diagnosis and Therapy Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Type

Figure 21: Global Market Share (%) By Type (2032)

Figure 22: Global Molecular Diagnosis and Therapy Market Value (USD Million) By Region

Figure 23: Global Molecular Diagnosis and Therapy Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

79 items

Table 1: Market Segmentation Analysis

Table 2: Global Molecular Diagnosis and Therapy Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Molecular Diagnosis and Therapy Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 4: Global Molecular Diagnosis and Therapy Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Type

Table 8: Global Market Share (%) By Type (2024)

Table 9: Global Molecular Diagnosis and Therapy Market Value (USD Million) By Region

Table 10: Global Molecular Diagnosis and Therapy Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Type

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Type

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Type

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 26: Global Molecular Diagnosis and Therapy Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Molecular Diagnosis and Therapy Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Molecular Diagnosis and Therapy Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Agilent Technologies Basic Information And Sales Area

Table 33: Agilent Technologies. Products Portfolio

Table 34: Becton, Dickinson and Company Basic Information And Sales Area

Table 35: Becton, Dickinson and Company. Products Portfolio

Table 36: Biomérieux Sa Basic Information And Sales Area

Table 37: Biomérieux Sa. Products Portfolio

Table 38: Danaher Corporation Basic Information And Sales Area

Table 39: Danaher Corporation. Products Portfolio

Table 40: Diasorin Basic Information And Sales Area

Table 41: Diasorin. Products Portfolio

Table 42: Grifols Basic Information And Sales Area

Table 43: Grifols. Products Portfolio

Table 44: Hologic Basic Information And Sales Area

Table 45: Hologic. Products Portfolio

Table 46: Illumina Basic Information And Sales Area

Table 47: Illumina. Products Portfolio

Table 48: Qiagen Basic Information And Sales Area

Table 49: Qiagen. Products Portfolio

Table 50: Roche Diagnostics Basic Information And Sales Area

Table 51: Roche Diagnostics. Products Portfolio

Table 52: Siemens AG Basic Information And Sales Area

Table 53: Siemens AG. Products Portfolio

Table 54: Thermo Fisher Scientific Basic Information And Sales Area

Table 55: Thermo Fisher Scientific. Products Portfolio

Table 56: Global Market Value (USD Million) (2025-2032) By Application

Table 57: Global Market Share (%) By Application (2032)

Table 58: Global Market Value (USD Million) (2025-2032) By Type

Table 59: Global Market Share (%) By Type (2032)

Table 60: Global Molecular Diagnosis and Therapy Market Value (USD Million) By Region

Table 61: Global Molecular Diagnosis and Therapy Market Share (%) By Region (2025-2032)

Table 62: North America Market Value (USD Million) (2025-2032) By Country

Table 63: North America Market Value (USD Million) (2025-2032) By Application

Table 64: North America Market Value (USD Million) (2025-2032) By Type

Table 65: Europe Market Value (USD Million) (2025-2032) By Country

Table 66: Europe Market Value (USD Million) (2025-2032) By Application

Table 67: Europe Market Value (USD Million) (2025-2032) By Type

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 69: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 70: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 71: South America Market Value (USD Million) (2025-2032) By Country

Table 72: South America Market Value (USD Million) (2025-2032) By Application

Table 73: South America Market Value (USD Million) (2025-2032) By Type

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 75: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 76: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 77: Research Programs/Design For This Report

Table 78: Key Data Information From Secondary Sources

Table 79: Key Data Information From Primary Sources

FAQs

1. What is the current Molecular Diagnosis and Therapy market size?

Valued at USD 18.4 billion in 2023, the Molecular Diagnosis and Therapy market size reflects surging uptake of PCR, NGS, and companion diagnostics across oncology, infectious disease, and pharmacogenomics.

2. What is the future outlook for the Molecular Diagnosis and Therapy market?

The future outlook projects a robust 10.2% CAGR through 2030, propelled by personalized medicine adoption, expanding reimbursement, and rising demand for early, minimally invasive disease detection worldwide.

3. Which factors are the primary growth drivers?

Key drivers include escalating cancer incidence, advances in real-time PCR and NGS, supportive regulatory frameworks, growing liquid-biopsy acceptance, and increasing payer willingness to reimburse high-value molecular tests.

4. What major challenges could restrain market expansion?

High instrument costs, complex reimbursement coding, stringent CLIA/FDA validation, shortage of skilled lab personnel, and data-privacy concerns collectively temper uptake, particularly in cost-sensitive emerging economies.

5. Which regions currently lead the Molecular Diagnosis and Therapy market?

North America dominates with 45% share, followed by Europe at 27%; Asia-Pacific is the fastest-growing region owing to expanding healthcare infrastructure, favorable regulations, and rising precision-medicine investments in China and Japan.

6. Who are the top companies shaping the competitive landscape?

Roche, Abbott, Thermo Fisher, Hologic, QIAGEN, Illumina, BioMérieux, Danaher, Agilent, and BD lead through broad assay menus, global lab partnerships, and aggressive M&A to secure platform differentiation.

7. What future opportunities should stakeholders monitor?

Point-of-care PCR cartridges, AI-guided companion diagnostics, multi-cancer early-detection liquid biopsies, and decentralized home-collection kits present high-growth niches poised to redefine care delivery economics.

8. How is technology evolution impacting diagnostics and therapeutics?

Nanopore sequencing, CRISPR-based SHERLOCK assays, and cloud-based bioinformatics compress turnaround times, cut costs, and enable real-time therapy selection, amplifying precision and scalability across healthcare networks.

9. What does the regulatory landscape look like for new entrants?

Parallel FDA breakthrough-device and EU IVDR pathways provide expedited CE-mark and 510(k) routes; however, rigorous clinical-evidence demands and post-market surveillance require robust QMS and risk-management documentation.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Molecular Diagnosis and Therapy Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	11.20 million
Revenue forecast in 2033	22.98 million
Growth rate	CAGR of 9.4% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Type
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Abbott Laboratories; Agilent Technologies; Becton, Dickinson and Company; Biomérieux Sa; Danaher Corporation; Diasorin; Grifols; Hologic; Illumina; Qiagen; Roche Diagnostics; Siemens AG; Thermo Fisher Scientific
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options